-
Aarti Industries Share: Pros and Cons Every Investor Must Know in 2026
- August 10, 2026
- Posted by: Neeraj Pandey
- Category: News
No Comments
Aarti Industries share pros and cons: India’s largest benzene specialty chemical company at 34x PE during transition-year ROE depression analysed for 2026.
-
Clean Science and Technology Share: Pros and Cons Every Investor Must Know in 2026
- August 10, 2026
- Posted by: Kunal Singla
- Category: News
Clean Science and Technology share pros and cons: green chemistry specialty leader at 35.22x PE with MEHQ and BHA global leadership analysed for 2026.
-
Sharda Cropchem Share: Pros and Cons Every Investor Must Know in 2026
- August 10, 2026
- Posted by: Neeraj Pandey
- Category: News
Sharda Cropchem share pros and cons: India’s cheapest quality company at 11.86x PE with 21.71% ROE and agrochemical registration moat analysed for 2026.
-
Laurus Labs Share: Pros and Cons Every Investor Must Know in 2026
- August 10, 2026
- Posted by: Neeraj Pandey
- Category: News
Laurus Labs share pros and cons: pharma ARV API leader transitioning to CDMO at very expensive 91x PE analysed for 2026.
-
Sumitomo Chemical India Share: Pros and Cons Every Investor Must Know in 2026
- August 10, 2026
- Posted by: Kunal Singla
- Category: News
Sumitomo Chemical India share pros and cons: Japan MNC agrochemical subsidiary at premium 45x PE with proprietary molecule access analysed for 2026.
-
10 Stocks to Buy Today 10 Aug 2026: Best Q1FY27 Picks
- August 10, 2026
- Posted by: Neeraj Pandey
- Category: News
10 stocks to buy today on 10 Aug 2026: Titan, Oil India, Hitachi Energy and Nitin Spinners on strong Q1FY27 results. Full analysis and buy rationale inside.
-
Lumax Industries Q1 FY27 Results: Revenue Rs 1,223 Cr, PAT Rs 39 Cr and Key Highlights
- August 10, 2026
- Posted by: Kunal Singla
- Category: News
Lumax Industries Q1 FY27 results: Revenue Rs 1,223 Cr (+32.60% YoY), PAT Rs 39 Cr (+76.22% YoY). Key highlights, financial analysis and FY27 outlook.
-
Emcure Pharma Share Price: USFDA Clears Sanand With VAI Status
- August 10, 2026
- Posted by: Neeraj Pandey
- Category: News
Emcure Pharma share price is in focus after the USFDA closed its Sanand, Gujarat facility inspection with VAI status, the most favourable outcome, on 10 August 2026.
-
Advanced Enzyme Q1 FY27 Results: Revenue Rs 189 Cr, PAT Rs 38 Cr and Key Highlights
- August 10, 2026
- Posted by: Neeraj Pandey
- Category: News
Advanced Enzyme Q1 FY27 results: Revenue Rs 189 Cr (+2.08% YoY), PAT Rs 38 Cr (-4.58% YoY). Key highlights, financial analysis and FY27 outlook.
-
Aditya Birla Fashion Q1 FY27 Results: Revenue Rs 2,025 Cr, Net Loss Rs 242 Cr and Key Highlights
- August 10, 2026
- Posted by: Kunal Singla
- Category: News
Aditya Birla Fashion Q1 FY27 results: Revenue Rs 2,025 Cr (+10.60% YoY), Net Loss Rs 242 Cr (-6.30% YoY). Key highlights, financial analysis and FY27 outlook.